XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30

$1.60−0.04 (-2.44%)

Close on Nov 13, 2026Market cap $15.14MP/E –Yield –

XTL Biopharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

XTL Biopharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?